Found 157 Neoplasms trials
A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
The primary objective of this study is to characterize the safety, tolerability, dose limiting toxicities (DLTs), and maximum tolerated dose (MTD) or maximum administered dose (MAD) (if no MTD is defined) of MGD013 when administered intravenously (IV) every 2 weeks to patients with unresectable, locally advanced or metastatic cancers.
This is a phase 1 study with Highly-selective RET inhibiter, Blu-667, in patients with Thyroid Cancer, Non-Small cell lung cancer and other advanced solid tumors. The study will be conducted at multiple centers in the United States and Europe. the purpose of this trial is to determine the maximum tolerated …
mNET is commonly treated with TACE or TACE. mNET cells can survive TACE or TARE ischemic conditions. In this study, we will biopsy mNETs being treated with TACE or TARE prior to treatment, after treatment, and again at recurrence to characterize the metabolic, immunologic, and genetic profile of the cells …
The main purpose of this study is to: 1) determine the feasibility of giving hydroxychloroquine, everolimus or the combination to people with disseminated tumor cells detected in their bone marrow. 2) determine how tolerable these drugs are in people who have completed treatment for breast cancer. 3) determine how well …
You are being asked to be in this study because you have epilepsy and you take epilepsy medication. Aquestive Therapeutics (the study Sponsor) has begun a research study of an investigational drug called Diazepam Buccal Soluble Film or DBSF as a possible treatment for patients with epilepsy. An investigational drug …
This is a small scale investigational study to compare different fluorescent camera imaging systems against the current standard (Visionsense VS3 Iridium system) for patients with Ovarian cancer. The VS3 is and FDA approved device currently in phase 3 clinical trials at the University of Pennsylvania and other institutions in combination …
The purpose of this program is to allow patients who, in consultation with their treating physician, feel it is in their best interest to continue to receive olaratumab. Only patients with soft tissue sarcoma who are already being treated with olaratumab may enter this program.
Request for collaborative review: WIRB serving as IRB of record.
The research study is being conducted to study the PD-1 antibody, AGEN2034 alone, or in combination with the CTLA-4 antibody, AGEN1884, in women with recurrent cervical cancer. Subjects will be asked to complete the following research procedures: 12 lead electrocardiogram (ECG) and evaluation of heart function (to determine heart health). …
Patients with recurrent or metastatic ER+ breast cancer, who have failed prior endocrine therapy may be eligible for this study. Patients may participate in this study, if they are at least 18 years of age, most participants will be receiving care at the clinical practices of the University of Pennsylvania. …
